335 results about "Influenza a" patented technology

The invention relates to mRNA comprising lipid nanoparticles and their medical uses. The lipid nanoparticles of the present invention comprise a cationic lipid according to formula (I), (II) or (III) and / or a PEG lipid according to formula (IV), as well as an mRNA compound comprising an mRNA sequence encoding an antigenic peptide or protein. The invention further relates to the use of said lipid nanoparticles as vaccines or medicaments, in particular with respect to influenza or rabies vaccination.

A bioenergy generator to increase the life force of a biological system is provided. The bioenergy generator includes fine pieces of natural stone, fine pieces of natural sand, fine pieces of metal, water and a supporting material operable to hold the natural sand, the natural stone, the metal, and the water together. Uses of the bioenergy generator are also provided, in particular, to treat long-COVID and influenza.

The invention belongs to the technical field of virus detection, and discloses a digital PCR (Polymerase Chain Reaction) kit for simultaneously detecting African horse pestivirus, West Nile virus and equine influenza H3N8, and the kit comprises primers and probes as shown in SEQ ID NO.1-SEQ ID NO.21. The invention also discloses a kit for simultaneously detecting African horse pestivirus, West Nile virus and equine influenza H3N8. According to the invention, after a single system of an African horse pestivirus VP7 gene, an African horse pestivirus-NS2 gene, a west nile virus-NS5 gene, a west nile virus-NS2a gene, an equine influenza H3N8-HA gene and an equine influenza H3N8-NA gene is tested, a seven-fold digital PCR (Polymerase Chain Reaction) system containing an internal standard is established; through tests of indexes such as linearity, specificity, minimum detection limit, repeatability, comparison of a single digital PCR system and a multiple digital PCR system, the currently developed digital PCR multiple detection kit completely meets development requirements and is high in specificity and sensitivity, and the minimum detection limit of the digital PCR multiple detection kit can reach 10 Copies / mu L or below.

The invention belongs to the field of biological medicine industry, and discloses a blood marker for assisting in diagnosing influenza. The inventor verifies that the LRG1 is a peripheral blood marker of influenza for the first time and can be used for auxiliary diagnosis of influenza and increase of the detection rate of influenza virus by being matched with multiple times of detection of influenza virus. A test result shows that the peripheral blood LRG1 content 5ng / ml is a CUTOFF value, 46 patients and 4 false negative patients are successfully detected for 50 influenza patients, and the sensitivity is 92%; the number of normal persons is 60, the number of the normal persons is 12, and the specificity is 80%. After influenza treatment, LRG1 and Plt are obviously reduced compared with those before influenza treatment; 0.001, which is equivalent to the level of normal people, Pgt; and 0.05%.

The present application provides chimeric proteins comprising an antibody moiety that specifically binds to a component of an influenza virus or a variant thereof, and a positively charged mucoadhesive peptide fragment. Compositions comprising the chimeric proteins described herein are useful for preventing or treating an infection caused by an influenza virus or a variant thereof in an individual.

The invention discloses a freeze-drying protection system for an influenza live attenuated vaccine. The freeze-drying protection system is composed of a buffer solution and auxiliary materials. The freeze-dried powder is safe and effective, has a relatively good protection effect on an influenza attenuated strain, is relatively low in virus loss before and after freeze-drying, and has good storage stability.

The present invention uses ex vivo human airway cultures to assess the human transmissibility and replication competence of influenza and coronavirus strains. By comparing pandemic influenza A subtype H1N1 and highly pathogenic avian influenza H5N1 as reference strains, the transmissibility risk of various viruses was evaluated and categorized. Additionally, an in vitro model evaluated virus-induced impairment of alveolar fluid clearance (AFC) as an indicator of disease severity. The study revealed correlations between bronchus viral replication, human transmission, AFC impairment, and clinical disease severity across different influenza and coronavirus strains.

Provided are an anti-neuraminidase human monoclonal antibody obtained by means of multiple rounds of in-vitro screening and recombinant modification, and the use thereof in the preparation of a product for preventing, detecting, or treating influenza viruses. The provided monoclonal antibody exhibits significant neuraminidase inhibitory activity and broad-spectrum binding capacity to influenza virus antigens, shows excellent preventive and therapeutic effects against multiple seasonal influenza viruses, provides a new technical option for resisting influenza infection, and has great application value.

The invention belongs to the technical field of drug synthesis, and particularly relates to an adamantane derivative as well as a synthesis method and application thereof. The adamantane derivative comprises an intermediate structural formula I, an intermediate structural formula II and an intermediate structural formula III, and the structural general formula is as follows: Linker is substituted or unsubstituted C6-C10 aroyl, R1 is hydrogen or C1-C6 alkyl, R2 is hydrogen, C1-C6 alkyl or a nitrogen-containing or nitrogen-free structural fragment, or the integral structure of R1R2 is N-substituted heterocyclic pentyl or heterocyclic cyclohexyl. According to the adamantane derivative provided by the invention, an adamantane structure is combined with part of groups of OAB-14, and a parent nucleus structure is changed, so that the drug activity is improved. The invention also provides a synthesis method of the compound, the obtained compound is screened through cell viability research, and the compound has a potential synergistic effect in the aspects of preventing influenza and treating Alzheimer's disease.

The invention provides an anti-influenza A virus nano antibody and application thereof, the nano antibody comprises a heavy chain variable region, the heavy chain variable region comprises CDR1, CDR2 and CDR3, and the CDR3 of the heavy chain variable region is selected from an amino acid sequence as shown in SEQ ID NO: 8 or SEQ ID NO: 16. The anti-influenza A virus nano antibody can be combined with various influenza A viruses, including subtype influenza viruses such as H1N1, H2N2, H3N2 and H7N9, has strong broad spectrum, has different binding epitopes of the two nano antibodies, and can be applied to double antibody sandwich method detection, enzyme-linked immunosorbent assay and colloidal gold detection. According to the invention, multivalent transformation is also carried out on the nano antibody to obtain a dodecavalent hexamer cyclic structure nano antibody, so that the application scene of the anti-influenza A virus nano antibody can be further extended.

The invention belongs to the technical field of vaccine adjuvants, and particularly relates to tubeimoside B liposome as well as a preparation method and application thereof. The preparation method comprises the following steps: dissolving phospholipid, cholesterol and PEGylated phospholipid in an organic solvent to form a mixed solution, and then evaporating the mixed solution to form a film; and hydrating the film by using an aqueous solution of tubeimoside B to finally prepare the tubeimoside B liposome. Compared with free tubeimoside B, the lipidosome has the advantages that the hemolysis percentage is obviously reduced, and antigen-specific humoral immune response and / or cellular immune response can be effectively enhanced when the lipidosome is used as a vaccine adjuvant. In an H1N1 influenza mouse model, the lipidosome combined antigen shows an excellent protection effect, which is shown in that the mouse weight fluctuation is relatively small and the lung virus load is remarkably reduced. The invention provides important theoretical basis and practical examples for developing low-toxicity and high-efficiency plant-derived vaccine adjuvants, and has a wide application prospect.

The invention relates to the technical field of biology, and particularly discloses a kit for detecting haemophilus influenzae based on PCR (Polymerase Chain Reaction) / RAA-CRISPR-Cas13a. The invention discloses a kit for detecting a haemophilus influenzae gene on the basis of PCR (Polymerase Chain Reaction) / RAA-CRISPR-Cas13a. The kit comprises a primer pair for specifically amplifying haemophilus influenzae genes and crRNA, the sequence of the crRNA is composed of an anchoring sequence used for being combined with Cas13a protein and a guide sequence of a target sequence of the haemophilus influenzae genes, and the guide sequence is shown as the 39-66th site of SEQ ID No.28. The invention constructs a method for detecting haemophilus influenzae genes by combining a PCR or RAA technology with a CRISPR-Cas13a technology, the method is simple, convenient and rapid, has higher sensitivity and specificity, can reach a single copy level in sensitivity, and can be used for clinically and rapidly identifying whether the haemophilus influenzae is infected or not.

This article provides a combination of compounds that can inhibit influenza virus replication, reduce influenza virus load, and / or treat influenza.

The application discloses a fusion protein for preventing and treating various pathogenic Pasteurellaceae bacterial infections, a nucleic acid vaccine and application thereof. The fusion protein comprises six antigens rplE, rpsC, rpsE, EF-Tu, DnaK and EF-G or three antigens EF-Tu, DnaK and EF-G, and the antigens are highly conservative in various Pasteurellaceae bacteria. The application further provides a recombinant nucleic acid molecule encoding the fusion protein, an immunogenic composition containing the same and a recombinant vaccine. The vaccine can induce broad-spectrum cross immune protection and is used for preventing and treating infectious diseases caused by Pasteurella multocida, Haemophilus parasuis, Mannheimia haemolytica, Haemophilus influenzae and Haemophilus paragallinarum.

The present invention belongs to the field of biomedicine. Provided are an influenza nanoparticle vaccine, and a preparation method therefor and the use thereof. A fusion protein containing an influenza virus strain HA protein or a fragment thereof, an antigenic epitope of the influenza virus protein, and ferritin, as an antigen, can induce an immune response effect against an influenza virus, and a vaccine composed of the fusion protein and an MF59 adjuvant can induce a protection effect against viral challenge and have a good cross-protection effect.

Described herein is a composition comprising nucleic acid sequences encoding at least two amino acid sequences selected from the group consisting of SEQ ID NOs: 1 to 49. Also described herein is a composition comprising nucleic acid sequences encoding at least two amino acid sequences selected from the group consisting of SEQ ID NOs: 81 to 143. Also described herein is a composition comprising nucleic acid sequences encoding at least two amino acid sequences selected from the group consisting of SEQ ID NOs: 137515 to 137675. Also described herein is a composition comprising nucleic acid sequences encoding at least two amino acid sequences selected from the group consisting of SEQ ID NOs: 137682 to 137830.

The invention discloses a compound of formula I; specifically, the invention relates to a compound as shown in a formula I or a stereoisomer, a tautomer, an isotope derivative and pharmaceutically acceptable salt thereof, and application of the compound as shown in the formula I and a composition of the compound as an anti-influenza virus drug. # imgabs0 #

The present invention relates to an immunogenic composition comprising two or more polypeptides. The invention also provides nucleic acid molecules and vectors encoding the polypeptides, and methods of using the compositions, nucleic acid molecules and vectors for the prevention or treatment of influenza.

The present disclosure relates to the field of RNAs for the prevention or treatment of various infectious agents. In particular, the present disclosure relates to methods and agents for vaccination against coronavirus infection, influenza infection and / or RSV infection and induction of effective coronavirus, influenza virus and / or RSV antigen-specific immune responses, such as antibodies and / or T cell responses. Specifically, in one embodiment, the disclosure relates to a method comprising administering to a subject (i) a bivalent RNA vaccine encoding a peptide or protein comprising an epitope of SARS-CoV-2 spike protein (S protein), and (ii) a tetravalent RNA vaccine encoding a peptide or protein comprising an epitope of hemagglutinin (HA), the present invention relates to a method for inducing an immune response in a subject against a coronavirus S protein, in particular an S protein of SARS-CoV-2, and an influenza protein, in particular an HA protein of influenza A and B viruses.

Disclosed is a combination vaccine for prevention of influenza and novel coronavirus infections. The combination vaccine for vaccination against influenza and novel corona viruses was obtained by inactivating all influenza virus particles and all novel coronavirus particles respectively, thereby inducing the antibodies to each virus without affecting each vaccine effect, so that the defensive effects were obtained against the attacks of each virus. In addition, the combination vaccine with this combination exhibited favorable neutralizing antibody induction and defensive effects to the attacks of these viruses even without addition of an adjuvant.

The invention discloses a large-scale closed public place aerosol virus enrichment monitoring system based on an STM32 main control platform, which combines an air sampler and a microfluidic analysis technology, adopts a temperature and humidity real-time monitoring module, optimizes an air sampling and virus enrichment process, and realizes that an integrated microfluidic analysis unit completes rapid determination of virus concentration. According to the system, virus concentration detection is carried out on an enriched sample by utilizing a double-antibody sandwich enzyme-linked immunoassay technology, and the virus concentration is determined through absorbance measurement. Experiments show that the detection error of the system is lower than 5%, and virus monitoring which is quick in response, convenient to operate and low in cost can be achieved. The system is suitable for monitoring viruses such as influenza, new coronavirus and norovirus in large closed public places, and provides efficient technical support for public health safety.

The present application relates to the technical field of air conditioners, and provides a control method of an elevator air conditioner and the elevator air conditioner, the control method of the elevator air conditioner comprising: in response to an elevator door opening signal, acquiring the body temperature of a person entering the elevator; determining that the body temperature of the person is greater than or equal to a preset temperature, then controlling a fan of the elevator air conditioner to stop running, and controlling an ultraviolet disinfection device to disinfect the air in the elevator for a preset time length after all the persons in the elevator leave the elevator. When the person enters the elevator, the temperature detection device acquires the body temperature of the person in time, if the body temperature of the person exceeds the preset temperature, the air in the elevator has the risk of influenza transmission, the fan of the elevator air conditioner is controlled to be closed in time, and the speed of air flow in the elevator is slowed down. After all the persons in the elevator leave the elevator, the air in the elevator is disinfected in time by the ultraviolet disinfection device, so that the subsequent passengers are prevented from contacting the air possibly carrying the influenza virus, and the risk of influenza transmission is reduced.

The present invention provides highly growing influenza reassortant viruses and highly growing influenza reassortant virus vectors comprising amino acid modifications in the PB2, PB1, M1 and / or NS2 proteins, which exhibit a highly increased growth rate compared to unmodified influenza viruses. Further provided are pharmaceutical compositions comprising the reassortant viruses and virus vectors containing said modifications and their use for vaccination purposes.

This application relates to methods for preparing viral proteins, such as influenza hemagglutinin proteins and / or influenza neuraminidase proteins, immunogenic compositions comprising the viral proteins thus obtained and vaccines comprising the same, as well as methods of using the same, in particular in the prevention and / or treatment of diseases or conditions caused by viruses, such as influenza viruses.

This application relates to methods for preparing viral proteins, such as influenza hemagglutinin proteins and / or influenza neuraminidase proteins, immunogenic compositions comprising the viral proteins thus obtained and vaccines comprising the same, as well as methods of using the same, in particular in the prevention and / or treatment of diseases or conditions caused by viruses, such as influenza viruses.

This invention provides an H3N2 influenza mRNA vaccine targeting the tandem HA and NA proteins and its preparation method, relating to the field of vaccine preparation technology. The H3N2 influenza mRNA vaccine is obtained by linking the conserved amino acid sequences of HA and NA of H3N2 with GGGSGGGSGGGSGGGS, and the amino acid sequence of the H3N2 influenza mRNA vaccine is shown in SEQ ID NO.1, and the nucleic acid sequence is shown in SEQ ID NO.2. This invention overcomes the shortcomings of existing technologies, improves the protective effect of the vaccine against H3N2 influenza, and enables it to better cope with immune evasion from the latest emerging H3N2 variants.

Provided herein are group 2 influenza hemagglutinin stem polypeptides, nucleic acids encoding said polypeptides, vectors comprising said nucleic acid and pharmaceutical compositions comprising the same, as well as methods of their use, in particular in the prevention and / or treatment of influenza virus infections.

The invention discloses an influenza reporter virus carrying a fluorescent RNA aptamer and a construction method and application thereof, and the influenza reporter virus carrying the fluorescent RNA aptamer is obtained by introducing a termination codon TAA into the 328th nucleotide of an ORF region of an NS1 gene on the basis of a genome of an influenza A virus and terminating in advance, then introducing a terminating codon TAA into the 328th nucleotide of the ORF region of the NS1 gene of the influenza A virus; original nucleotides at the 328-480 sites are replaced by forward or reverse RNA aptamers, and the RNA aptamer is obtained. The influenza reporter virus carrying the fluorescent RNA aptamer constructed by the invention also has the characteristics of good virus replication ability, high RNA imaging sensitivity and good specificity on the basis of stable inheritance, can be used for real-time visual observation of virus RNA, and is used for research on virus replication cycle and molecular mechanism related to the virus RNA. Besides, the construction method of the influenza reporter virus carrying the fluorescent RNA aptamer can also be applied to construction of RNA fluorescent reporter viruses of other subtype influenza viruses such as H3N2 and H5N1, and an important tool is provided for real-time tracing of corresponding virus RNA.

The invention relates to an influenza risk prediction method based on multi-source data, and the method comprises the following steps: determining a target influenza type, and determining the type of associated multi-source data according to the target influenza type; determining a weight value corresponding to each data type; calculating a standard value for each data category based on its healthy user sample; obtaining multi-source data of a target user, and further determining a data value corresponding to the multi-source data type of the target user; calculating an offset coefficient between a data value corresponding to each data type of the target user and a standard value of the data value to obtain an offset coefficient of each data type of the target user; calculating an influenza risk value according to the offset coefficient of each data type of the target user and the weight value; and judging whether the flu risk value is greater than a preset risk threshold, if so, judging that the flu risk exists, and if not, judging that the flu risk does not exist. According to the invention, a certain prevention effect on influenza of a user can be achieved.